Quarterly ResultAug 4, 2026, 08:23 AM
Harmony Biosciences Q2 Revenue $261.3M, Net Income $75.4M
AI Summary
Harmony Biosciences reported strong financial results for the second quarter and first half of 2026, with significant increases in net product revenue and net income. The company continues to expand its pipeline through strategic agreements, including a sublicense for an orexin 2 receptor agonist, the acquisition of Epygenix Therapeutics for rare epilepsy, and collaborations for next-generation pitolisant products and cell replacement therapies. These initiatives aim to address unmet needs in neurological diseases and diversify its portfolio beyond WAKIX.
Key Highlights
- Q2 2026 net product revenue increased 30.3% to $261.3 million from $200.5 million in Q2 2025.
- Q2 2026 net income grew 89.4% to $75.4 million, up from $39.8 million in Q2 2025.
- Diluted EPS for Q2 2026 was $1.28, compared to $0.68 in Q2 2025.
- Net cash provided by operating activities for H1 2026 was $120.2 million, up from $113.3 million in H1 2025.
- Total cash, cash equivalents, and investments reached $962.5 million as of June 30, 2026.
- Expanded into orexin science with a sublicense for BP-205 in April 2024.
- Acquired Epygenix Therapeutics in April 2024, adding rare epilepsy treatments.
- Secured Novitium License Agreement in January 2026 for an amorphous pitolisant formulation.
Price Impact
More from HRMY